Is Palantir Stock a Millionaire Maker?
Palantir (NASDAQ:PLTR) has shot upward over the last year and…
Sell
42
HOLX Quote, Financials, Valuation and Earnings
Last price:
$52.58
Seasonality move
:
5.33%
Day range:
$56.96 - $57.93
52-week range:
$55.89 - $84.67
Dividend yield:
0%
P/E ratio:
18.07x
P/S ratio:
3.34x
P/B ratio:
2.69x
Volume:
2.5M
Avg. volume:
3.2M
1-year change:
-24.91%
Market cap:
$12.9B
Revenue:
$4B
EPS (TTM):
$3.17
Analysts' Opinion
-
Consensus RatingHologic has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 14 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $75.40, Hologic has an estimated upside of 31.64% from its current price of $57.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $57.28.
Fair Value
-
According to the consensus of 17 analysts, Hologic has 31.64% upside to fair value with a price target of $75.40 per share.
HOLX vs. S&P 500
-
Over the past 5 trading days, Hologic has underperformed the S&P 500 by -3.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hologic does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hologic has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Hologic reported revenues of $1B.
Earnings Growth
-
Hologic earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Hologic reported earnings per share of $0.87.
Enterprise value:
13.4B
EV / Invested capital:
--
Price / LTM sales:
3.34x
EV / EBIT:
12.79x
EV / Revenue:
3.32x
PEG ratio (5yr expected):
0.36x
EV / Free cash flow:
12.13x
Price / Operating cash flow:
12.21x
Enterprise value / EBITDA:
9.99x
Gross Profit (TTM):
$2.2B
Return On Assets:
8.46%
Net Income Margin (TTM):
18.42%
Return On Equity:
15.28%
Return On Invested Capital:
10.04%
Operating Margin:
22.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $4.5B | $4B | $4B | $1B | $1B | |
| Gross Profit | $2.6B | $2B | $2.2B | $567.5M | $580.5M | |
| Operating Income | $1.3B | $724.8M | $938M | $226.7M | $233.7M | |
| EBITDA | $1.7B | $1.1B | $1.3B | $305.7M | $352M | |
| Diluted EPS | $3.92 | $2.11 | $3.17 | $1.03 | $0.87 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.6B | $3.5B | $4B | $3.5B | $3.5B | |
| Total Assets | $7.6B | $9.3B | $9.3B | $8.5B | $8.7B | |
| Current Liabilities | $1.1B | $1.3B | $956.2M | $899M | $1B | |
| Total Liabilities | $4.3B | $4.8B | $4.2B | $3.8B | $4B | |
| Total Equity | $3.3B | $4.5B | $5.1B | $4.7B | $4.8B | |
| Total Debt | $2.8B | $3.1B | $2.8B | $2.6B | $2.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.8B | $1B | $1.3B | $220M | $189.3M | |
| Cash From Investing | -$73.8M | -$215.3M | -$698.8M | -$104.2M | -$22M | |
| Cash From Financing | -$726M | -$1.3B | -$701.8M | -$943.8M | -$537M | |
| Free Cash Flow | $1.7B | $858.7M | $1.1B | $182M | $142.3M | |
HOLX
Sector
Market Cap
$12.9B
$35.2M
Price % of 52-Week High
67.65%
44.63%
Dividend Yield
0%
0%
Shareholder Yield
4.51%
-0.81%
1-Year Price Total Return
-24.91%
-39.07%
Beta (5-Year)
0.544
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$58.07
200-day SMA
Sell
Level
$73.27
Bollinger Bands (100)
Sell
Level
60.06 - 72.18
Chaikin Money Flow
Buy
Level
445.2M
20-day SMA
Sell
Level
$58.44
Relative Strength Index (RSI14)
Sell
Level
39.75
ADX Line
Sell
Level
21.54
Williams %R
Neutral
Level
-61.4958
50-day SMA
Sell
Level
$60.82
MACD (12, 26)
Sell
Level
-0.98
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
264.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.4094)
Buy
CA Score
(Annual)
Level (0.4447)
Buy
Beneish M-Score
(Annual)
Level (-2.7631)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.9721)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Stock Forecast FAQ
In the current month, HOLX has received 3 Buy ratings 14 Hold ratings, and 0 Sell ratings. The HOLX average analyst price target in the past 3 months is $75.40.
-
Where Will Hologic Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hologic share price will rise to $75.40 per share over the next 12 months.
-
What Do Analysts Say About Hologic?
Analysts are divided on their view about Hologic share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hologic is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Hologic's Price Target?
The price target for Hologic over the next 1-year time period is forecast to be $75.40 according to 17 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is HOLX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hologic is a Hold. 14 of 17 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HOLX?
You can purchase shares of Hologic via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hologic shares.
-
What Is The Hologic Share Price Today?
Hologic was last trading at $52.58 per share. This represents the most recent stock quote for Hologic. Yesterday, Hologic closed at $57.28 per share.
-
How To Buy Hologic Stock Online?
In order to purchase Hologic stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is QuantumScape a Buy Now?
QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…
Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
62
RGC alert for May 2
Regencell Bioscience Holdings [RGC] is down 19.35% over the past day.
Buy
65
MYRG alert for May 2
MYR Group [MYRG] is up 3.13% over the past day.
Sell
35
FTAI alert for May 2
FTAI Aviation [FTAI] is up 6.17% over the past day.
